Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets
| Status: | Recruiting |
|---|---|
| Conditions: | Blood Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 4 - 17 |
| Updated: | 4/2/2016 |
| Start Date: | July 2011 |
| Contact: | Sara J Soliman, BSN |
| Email: | sjsoliman@cmh.edu |
| Phone: | 816-855-1977 |
The purpose of this study is to compare the pharmacokinetics of a routinely used compounded
liquid formulation of 6-mercaptopurine (6-MP) with commercially available tablets in
patients who are receiving treatment with 6-MP as part of their clinical treatment for acute
lymphoblastic leukemia (ALL).
liquid formulation of 6-mercaptopurine (6-MP) with commercially available tablets in
patients who are receiving treatment with 6-MP as part of their clinical treatment for acute
lymphoblastic leukemia (ALL).
Inclusion Criteria:
- Patients ages 4-17 years of age who are receiving maintenance chemotherapy treatment
for ALL with 6-MP will be included.
Exclusion Criteria:
- Inability to have blood drawn for the screening lab tests
- Received methotrexate or folate supplement within the last 24 hours
- Pregnant or lactating females
- Inability to swallow a pill
- Hemoglobin less or equal to 8 gm/dl
- Presence of significant co-morbid illness that makes child ineligible as deemed by
the investigator
- Weight < or = 16 kg
We found this trial at
1
site
Children's Mercy Hospital Children's Mercy Hospitals and Clinics continues redefining pediatric medicine throughout the Midwest...
Click here to add this to my saved trials
